Optune® (TTFields + Temozolomide)

About Novocure

Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.

Therapeutic Areas